BCM
PGNX

BlueCrest Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlueCrest Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,363
Closed -$130K – 2000
2018
Q1 		$130K Buy
+17,363
New +$115K ﹤0.01% 1331

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

BlueCrest Capital Management's PGNX Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2018, closing a stake of 17,363 shares — an estimated $130K sold.

BlueCrest Capital Management first reported a position in PGNX in Q1 2018 and held it in 1 quarter. The position peaked at $130K in Q1 2018. 155 funds tracked by Wall St. Rank hold PGNX as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 17,363 Progenics Pharmaceuticals Inc shares in Q2 2018, an estimated $130K.
  • BlueCrest Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Progenics Pharmaceuticals Inc position peaked at $130K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.